fda compounding glp-1 enforcement news today Targets Telehealth Compounded Marketing in New Warning Letters FDA is short-sighted on compounding

Blackman, A

There is no evidence that reaching a higher dose faster produces a better outcome

GLP-1 receptor agonists such as Semaglutide (Wegovy, Ozempic) have sparked major changes in weight loss treatments

However, the authors noted that absolute and relative estimates differed for anxiety and insomnia in this head-to-head comparison, so these small differences should be interpreted cautiously

Both AMP-activated protein kinase (AMPK) and the mammalian target of rapamycin (mTOR) and its downstream target p70 ribosomal protein S6 Kinase 1 (S6K1) contribute to detecting cellular energy and integrate nutrient and hormonal signals in order to maintain energy homeostasis in the organism